Regenerative Colonproctology with Lipogems®: An Innovative Approach to Treating Anorectal Conditions
Thanks to his experience and research in the field of regenerative medicine, Dr. Giori integrates Lipogems® therapy into the management of conditions such as rectovaginal fistulas, chronic anal pain, pilonidal sacrococcygeal cysts, and anal stenosis, ensuring optimal results and faster recovery for patients.
Anorectal conditions such as hemorrhoids, anal fistulas, fissures, and fecal incontinence often require surgical treatment, but healing can be slow due to the environmental challenges of the anal area. The use of Lipogems® significantly improves post-operative recovery by stimulating cellular regenerative processes, reducing post-operative pain through the anti-inflammatory properties of mesenchymal stem cells, and creating a more favorable tissue environment for healing. This minimally invasive and personalized approach may, in some cases, eliminate the need for more aggressive surgical procedures.
Scientific Studies Supporting Regenerative Therapy with Lipogems®
The effectiveness of regenerative proctology is supported by multiple scientific studies. These demonstrate that Lipogems® is a validated and innovative solution for the treatment of complex anorectal conditions. By combining advanced surgical techniques with regenerative therapy, patients benefit from better clinical outcomes, faster recovery times, and fewer post-operative complications.
Lipogems® in the Treatment of Fecal Incontinence
View full study (PDF)
A pilot study evaluated the effectiveness of micro-fragmented adipose tissue infiltration in treating fecal incontinence caused by trauma or post-surgical damage. Lipogems® injections into the anal sphincter muscles led to very promising outcomes. After 24 months, the treated patients experienced significant improvement in continence, pain reduction, and long-term functional recovery. This study opened the door to the application of regenerative medicine in proctologic surgery, showing the potential of mesenchymal cells in repairing anorectal tissues.
ATTIC Clinical Trial: Lipogems® for Complex Perianal Fistulas
Italian multicenter study (2023–2024)
The ATTIC clinical trial, conducted in six centers of excellence across Italy, involved 80 patients affected by Crohn’s Disease with complex perianal fistulas that were unresponsive to standard treatments. This double-blind randomized study aimed to assess the efficacy of autologous micro-fragmented adipose tissue infiltration after precise surgical cleaning of the fistula. The primary goals were to reduce inflammation, promote healing, and improve the success rate compared to conventional therapies. This research represents one of the most advanced studies in the field of regenerative proctology and has the potential to revolutionize the treatment of complex fistulas by offering a biological and minimally invasive solution to a condition that has long been difficult to manage.
